Here are a few analogies for iBio:

• Imagine a smaller Lonza, a biotech company that offers contract development and manufacturing services to other firms, while also developing its own portfolio of biopharmaceutical drugs and vaccines.

• It's like a biotech that provides the contract manufacturing services of Catalent to other companies, but also has its own drug and vaccine pipeline, similar to a small Moderna.

• Contract Development and Manufacturing Services (CDMO): iBio provides comprehensive process development, manufacturing, filling and finishing, and bio analytic services to collaborators and third-party customers.
• IBIO-100: This is a lead therapeutic candidate being developed for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.
• IBIO-200 and IBIO-201: These are preclinical vaccine candidates aimed at preventing severe acute respiratory syndrome coronavirus 2.
• IBIO-400: A developing therapeutic candidate intended for the treatment of classical swine fever.
• Recombinant Proteins: The company develops and offers recombinant proteins for third parties, both from a catalog and on a custom basis.

iBio (IBIO) sells primarily to other companies and research institutions, providing contract development and manufacturing services, recombinant proteins, and bio-analytic services.

Based on the provided information, its major customers and collaborators include:

• Planet Biotechnology, Inc. (Private company)
• The Texas A&M University System (Research institution)
• University of Natural Resources and Life Sciences, Vienna (Research institution)
• CC-Pharming Ltd. (Private company)

Martin B. Brenner, Chief Executive Officer and Chief Scientific Officer

Dr. Brenner has extensive experience leading drug discovery and development teams at major pharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. He served as the Chief Scientific Officer at Pfenex Inc., a company that was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Dr. Brenner also held the role of Chief Scientific Officer at Recursion Pharmaceuticals, Inc., and was the Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc. He previously established a biotech unit from scratch during his tenure at Merck. Dr. Brenner assumed the CEO role at iBio in June 2023.

Felipe Duran, Chief Financial Officer

Mr. Duran was appointed Chief Financial Officer of iBio in June 2023, after serving as the company's Vice President of Financial Planning and Analysis (FP&A) from April 2021 to February 2023 and then as interim CFO. Before joining iBio, he served as the Executive Director (CFO) of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, from 2016 to 2021. During his time at Lupin, he significantly increased regional net sales and successfully transformed a subsidiary into an EBITDA-positive business. Mr. Duran also managed Lupin's U.S. R&D finance group. His prior experience includes various strategy positions at Teva Pharmaceuticals and an FP&A Manager role at Bupa and Noven Pharmaceuticals.

Marc Banjak, Chief Legal Officer

Mr. Banjak brings over 15 years of experience in the biotechnology and contract research industries to iBio. He previously served as the inaugural general counsel for both Istari Oncology and Dova Pharmaceuticals. While at Dova, Mr. Banjak provided guidance through significant corporate and clinical milestones, including FDA and EMA approvals, a secondary public offering, and the company's acquisition by Swedish Orphan Biovitrum AB.

The key risks for iBio (IBIO) are primarily centered around the inherent uncertainties of biotechnology development, its financial stability as a preclinical-stage company, and its reliance on external intellectual property and collaborations.

1. Clinical Development and Regulatory Approval Risk: iBio operates as a preclinical-stage biotechnology company focused on developing antibody therapies, particularly for cardiometabolic diseases and obesity. Its current therapeutic candidates are in preclinical development, and the company has not completed clinical trials for any of its product candidates using its technology. There is a high risk of failure in the preclinical and clinical development stages, and it is uncertain if any of its product candidates will successfully advance to later stages, receive regulatory approvals, or ever be commercialized.
2. Financial Risk and Need for Capital: iBio has reported significant historical losses and negative net margins, with its revenue primarily generated from collaborative research and development agreements rather than commercial product sales. The company is heavily reliant on capital raises to fund its high-cost research and development activities. This financial position, characterized by substantial losses and dependence on external funding, indicates a potential risk to its long-term viability and ability to sustain operations.
3. Reliance on Third-Party Licenses and Intellectual Property: iBio's business strategy and the advancement of its product pipeline, including candidates like IBIO-600 and IBIO-610, are significantly dependent on intellectual property licensed from third parties, such as AstralBio. The termination of these exclusive license agreements or disputes over intellectual property could lead to the loss of critical development and commercialization rights, adversely affecting the company's ability to bring these products to market and its overall financial health.

The widespread market saturation and successful global deployment of highly effective SARS-CoV-2 vaccines from major pharmaceutical companies pose a significant threat to the commercial viability of iBio's preclinical vaccine candidates, IBIO-200 and IBIO-201. With established players already dominating the market and fulfilling demand, new preclinical candidates face an extremely challenging and potentially obsolete path to market entry and profitability.

iBio (symbol: IBIO) operates in several addressable markets for its main products and services:

• IBIO-100 (Systemic Scleroderma): The global scleroderma therapeutics market, which includes treatments for systemic scleroderma, was valued at approximately USD 33.50 billion in 2025 and is projected to grow to USD 52.23 billion by 2031. Systemic scleroderma accounted for 72.10% of this market in 2025. Another source indicates the global Systemic Scleroderma Treatment Market was valued at USD 1.73 billion in 2024 and is projected to reach USD 2.95 billion by 2035.
• IBIO-100 (Idiopathic Pulmonary Fibrosis - IPF): The global Idiopathic Pulmonary Fibrosis market is estimated to be valued at USD 4.95 billion in 2025 and is expected to reach USD 8.88 billion by 2032. Another estimate places the global market size at USD 4.54 billion in 2024, projected to grow to USD 8.6 billion by 2033.
• IBIO-200 and IBIO-201 (SARS-CoV-2 Vaccine Candidates): The Global COVID-19 Vaccine Market reached approximately USD 13.43 billion in 2024 and is expected to reach USD 29.98 billion by 2033.
• IBIO-400 (Classical Swine Fever): The global Classical Swine Fever Vaccines market was valued at USD 153 million in 2024 and is projected to grow to USD 214 million by 2032. The global Classical Swine Fever Live Vaccine market is predicted to grow from US$ 171 million in 2025 to US$ 226 million in 2031.
• Contract Development and Manufacturing Services (CDMO): The global biopharmaceutical contract development and manufacturing organization (CDMO) market size was estimated at USD 25.1 billion in 2024 and is projected to reach USD 56.6 billion by 2033.

iBio, Inc. (IBIO) has undergone a significant strategic pivot, transitioning from a company offering contract development and manufacturing organization (CDMO) services to an AI-driven antibody discovery and development firm primarily focused on cardiometabolic diseases and obesity. This shift largely completed by late 2025 means that future revenue growth will primarily be driven by the advancement and potential commercialization or partnering of its pipeline assets and the capabilities of its AI platform.

The expected drivers of future revenue growth for iBio over the next 2-3 years include:

1. Successful Advancement of Lead Therapeutic Candidates: iBio's future revenue is heavily reliant on the successful progression of its lead therapeutic candidates, IBIO-600 (anti-myostatin antibody) and IBIO-610 (activin E antibody), through clinical trials. IBIO-600 is anticipated to enter Phase 1a clinical trials in the first half of 2026, while IBIO-610 is slated for first-in-human clinical trials in early 2027. Positive results from these trials are crucial for demonstrating the therapeutic and commercial potential of these assets.

2. Strategic Partnerships and Out-Licensing Agreements: Given its preclinical and early clinical stage, iBio anticipates revenue growth through strategic partnerships and out-licensing agreements for its pipeline assets. These collaborations could involve upfront payments, milestone payments upon achieving certain development or regulatory benchmarks, and potential royalties on future sales. The recent $26 million private placement financing, led by a biotech investor, demonstrates confidence in its preclinical programs and helps extend its cash runway to support these developments.

3. Leveraging its AI-Driven Antibody Discovery Platform: iBio's proprietary AI-driven antibody discovery platform, the RubrYc® Discovery Engine, is a core asset. This platform has the potential to generate non-dilutive revenue through collaborative research agreements with other organizations seeking to discover and develop novel antibody therapies. Additionally, the platform's ability to identify new, differentiated therapeutic candidates could expand iBio's internal pipeline, offering further opportunities for future partnerships or commercialization.

4. Expansion of Pipeline into New Therapeutic Areas: While its immediate focus is on cardiometabolic diseases and obesity, the versatility of iBio's AI-driven platform allows for the discovery of new antibody treatments for other hard-to-target diseases, including cancer. Successfully expanding its pipeline into these new areas and advancing these candidates could open additional avenues for partnerships and future revenue streams.

Share Issuance

• In January 2026, iBio entered into a private placement agreement expected to generate approximately $26 million in gross proceeds (approximately $24.4 million net proceeds) through the sale of 11,061,738 shares of common stock or pre-funded warrants.
• In August 2025, iBio closed an underwritten public offering that secured initial gross proceeds of approximately $50 million, with the potential to raise an additional $50 million upon the full exercise of accompanying warrants, totaling up to $100 million in potential gross proceeds.
• In February 2026, iBio filed a preliminary prospectus to allow for the future offering and sale of up to $200 million in various securities, including common stock, preferred stock, debt securities, warrants, or units.

Inbound Investments

• The January 2026 private placement, raising approximately $26 million, was led by Frazier Life Sciences and included participation from other existing healthcare-focused institutional investors.
• The August 2025 public offering, which brought in initial gross proceeds of approximately $50 million, was led by Balyasny Asset Management, with significant participation from institutional investors such as Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge Group, Marshall Wace, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital.

Capital Expenditures

• Proceeds from the January 2026 private placement ($26 million gross) are allocated to advance preclinical cardiometabolic programs, specifically IBIO-610, IBIO-600, and myostatin/activin A bispecific programs, as well as to progress other preclinical pipeline assets and cover general working capital requirements.
• The net proceeds from the August 2025 public offering (initial $50 million gross, up to $100 million potential) are similarly earmarked for advancing preclinical cardiometabolic programs (IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs), along with other preclinical pipeline assets and general corporate purposes.
• Research and Development (R&D) expenses increased due to significant investment in advancing preclinical research activities, including non-human primate (NHP) studies and Chemistry, Manufacturing, and Controls (CMC) activities for programs such as IBIO-600 and IBIO-610. For instance, R&D expenses rose to $3.6 million in Q1 Fiscal Year 2026 from $1.3 million in the prior year and to $4.3 million in Q2 Fiscal Year 2026 from $1.9 million in the prior year.